Abivax (ABVX) Invested Capital (2021 - 2026)

Abivax's Invested Capital history runs 6 years deep, the most recent figure standing at $502.9 million for Q1 2026.

• In Q1 2026, Invested Capital rose 1132.5% year-over-year to $502.9 million; the TTM figure through Mar 2026 stood at $502.9 million (up 1132.5% YoY), while the FY2025 annual figure was $567.2 million, up 243.34% from the prior year.
• Invested Capital was $502.9 million for Q1 2026 at Abivax, down from $567.2 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $632.0 million in Q3 2025 to a low of $2.4 million in Q2 2025.
• Historically, Invested Capital has averaged $270.8 million across 5 years, with a median of $181.7 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Invested Capital slumped 98.68% in 2025, then surged 1132.5% in 2026.
• A 5-year view of Invested Capital shows it stood at $50.8 million in 2022, then jumped by 478.27% to $293.8 million in 2023, then sank by 43.77% to $165.2 million in 2024, then surged by 243.34% to $567.2 million in 2025, then slipped by 11.33% to $502.9 million in 2026.
• The last three Invested Capital figures came in at $502.9 million (Q1 2026), $567.2 million (Q4 2025), and $632.0 million (Q3 2025), per Business Quant data.